share_log

Kura Oncology Analyst Ratings

Kura Oncology Analyst Ratings

库拉肿瘤学分析师评级
Benzinga Analyst Ratings ·  2023/01/31 04:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 89.83% Stifel → $25 Initiates Coverage On → Buy
07/13/2022 120.2% Credit Suisse $27 → $29 Maintains Outperform
07/12/2022 127.79% Cantor Fitzgerald → $30 Initiates Coverage On → Overweight
02/25/2022 105.01% Credit Suisse $25 → $27 Maintains Outperform
02/25/2022 112.6% SVB Leerink $41 → $28 Maintains Outperform
02/15/2022 165.76% Jefferies → $35 Initiates Coverage On → Buy
11/26/2021 59.45% Credit Suisse $40 → $21 Maintains Outperform
11/24/2021 142.98% HC Wainwright & Co. $43 → $32 Maintains Buy
08/06/2021 203.72% Credit Suisse $42 → $40 Maintains Outperform
08/06/2021 211.31% SVB Leerink $40 → $41 Maintains Outperform
02/26/2021 203.72% SVB Leerink $42 → $40 Maintains Outperform
02/24/2021 226.5% HC Wainwright & Co. $45 → $43 Maintains Buy
12/07/2020 241.69% HC Wainwright & Co. $40 → $45 Maintains Buy
12/03/2020 241.69% Stifel → $45 Initiates Coverage On → Buy
10/12/2020 203.72% HC Wainwright & Co. $22 → $40 Maintains Buy
10/08/2020 226.5% Credit Suisse $27 → $43 Maintains Outperform
07/07/2020 105.01% Credit Suisse → $27 Initiates Coverage On → Outperform
06/01/2020 105.01% Oppenheimer $23 → $27 Maintains Outperform
05/06/2020 112.6% Wedbush $30 → $28 Maintains Outperform
05/05/2020 74.64% Oppenheimer $27 → $23 Maintains Outperform
05/05/2020 67.05% HC Wainwright & Co. $29 → $22 Reiterates → Buy
05/05/2020 82.23% Barclays → $24 Initiates Coverage On → Overweight
09/05/2019 67.05% JMP Securities → $22 Reinstates → Market Outperform
07/18/2019 112.6% Deutsche Bank → $28 Initiates Coverage On → Buy
11/09/2018 89.83% Piper Sandler → $25 Initiates Coverage On → Overweight
08/01/2018 135.38% HC Wainwright & Co. → $31 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/31/2023 89.83% Stifel → $25 开始承保 →购买
07/13/2022 120.2% 瑞士信贷 $27 → $29 维护 跑赢大盘
07/12/2022 127.79% 康托·菲茨杰拉德 → $30 开始承保 →超重
02/25/2022 105.01% 瑞士信贷 $25 → $27 维护 跑赢大盘
02/25/2022 112.6% SVB Leerink $41 → $28 维护 跑赢大盘
02/15/2022 165.76% 杰富瑞 → $35 开始承保 →购买
11/26/2021 59.45% 瑞士信贷 $40 → $21 维护 跑赢大盘
11/24/2021 142.98% HC Wainwright公司 $43 → $32 维护 买
08/06/2021 203.72% 瑞士信贷 $42 → $40 维护 跑赢大盘
08/06/2021 211.31% SVB Leerink $40 → $41 维护 跑赢大盘
02/26/2021 203.72% SVB Leerink $42 → $40 维护 跑赢大盘
02/24/2021 226.5% HC Wainwright公司 $45 → $43 维护 买
12/07/2020 241.69% HC Wainwright公司 $40 → $45 维护 买
12/03/2020 241.69% Stifel → $45 开始承保 →购买
10/12/2020 203.72% HC Wainwright公司 $22 → $40 维护 买
10/08/2020 226.5% 瑞士信贷 $27 → $43 维护 跑赢大盘
07/07/2020 105.01% 瑞士信贷 → $27 开始承保 →跑赢大盘
06/01/2020 105.01% 奥本海默 $23 → $27 维护 跑赢大盘
05/06/2020 112.6% 韦德布什 $30 → $28 维护 跑赢大盘
05/05/2020 74.64% 奥本海默 $27 → $23 维护 跑赢大盘
05/05/2020 67.05% HC Wainwright公司 $29 → $22 重申 →购买
05/05/2020 82.23% 巴克莱 → $24 开始承保 →超重
09/05/2019 67.05% JMP证券 → $22 恢复 →市场跑赢大盘
07/18/2019 112.6% 德意志银行 → $28 开始承保 →购买
11/09/2018 89.83% 派珀·桑德勒 → $25 开始承保 →超重
08/01/2018 135.38% HC Wainwright公司 → $31 开始承保 →购买

What is the target price for Kura Oncology (KURA)?

库拉肿瘤(Kura)的目标价是多少？

The latest price target for Kura Oncology (NASDAQ: KURA) was reported by Stifel on January 31, 2023. The analyst firm set a price target for $25.00 expecting KURA to rise to within 12 months (a possible 89.83% upside). 6 analyst firms have reported ratings in the last year.

Stifel于2023年1月31日报道了库拉肿瘤学(纳斯达克：KURA)的最新目标价。这家分析公司将目标价定为25.00美元，预计Kura将在12个月内上涨(可能上涨89.83%)。6家分析公司在过去一年公布了评级。

What is the most recent analyst rating for Kura Oncology (KURA)?

库拉肿瘤学(Kura)的最新分析师评级是多少？

The latest analyst rating for Kura Oncology (NASDAQ: KURA) was provided by Stifel, and Kura Oncology initiated their buy rating.

Stifel提供了对Kura Oncology(纳斯达克：KURA)的最新分析师评级，Kura Oncology启动了他们的买入评级。

When is the next analyst rating going to be posted or updated for Kura Oncology (KURA)?

Kura Oncology(Kura)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Kura Oncology的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Kura Oncology的上一次评级是在2023年1月31日提交的，所以你应该预计下一次评级将在2024年1月31日左右的某个时候提供。

Is the Analyst Rating Kura Oncology (KURA) correct?

分析师对Kura Oncology(Kura)的评级正确吗？

While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a initiated with a price target of $0.00 to $25.00. The current price Kura Oncology (KURA) is trading at is $13.17, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Kura肿瘤学(Kura)评级是以0.00美元至25.00美元的目标价启动的。Kura Oncology(Kura)目前的交易价格为13.17美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发